ARQT Nasdaq· Arcutis Biotherapeutics Inc.
FundamentalsNews digest Peer analysis
ARQT Nasdaq· Arcutis Biotherapeutics Inc.
Earnings report Q4 2023

ARQT Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

ARQT reported robust revenue growth across its different segments in the latest quarter. The company's primary source of revenue came from product sales, which accounted for the majority of its total revenue. Additionally, the company generated revenue from distribution services fees and prompt pay discounts.


ARQT's revenue increased significantly in the latest quarter, showcasing the company's strong performance. The growth in product sales can be attributed to the increasing demand for its biopharmaceutical products. The company's management highlighted the successful execution of its sales and marketing strategies, which contributed to the revenue growth. Furthermore, ARQT's ability to provide distribution services and prompt pay discounts to its customers added to its revenue stream.


While ARQT experienced overall revenue growth, it faced challenges related to product returns. The company had to provide return credits to customers, which impacted its gross product revenue and accounts receivable. Managing product returns effectively will be crucial for ARQT to mitigate any potential negative impact on its financial performance.


It is worth mentioning that ARQT's common stock has been publicly traded on the Nasdaq Global Select Market since its IPO in January 2020. As of February 21, 2024, there were approximately 71 holders of record of the company's common stock.


ARQT delivered strong revenue growth in the latest quarter, driven by increased product sales, distribution services fees, and prompt pay discounts. The company's successful execution of sales and marketing strategies contributed to its revenue growth. However, ARQT faced challenges related to product returns, which impacted its gross product revenue and accounts receivable. Overall, ARQT's performance in the latest quarter reflects its ability to capitalize on market demand and effectively manage its revenue streams.

Source documents

Form 10-K  filed on Feb 27, 2024
21 pages scanned

Reference data

Company financials Q4 revenue 13.5M
Analyst estimates Q4 EPS missed by -21.17%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.